Measuring quality of life in children with spinal muscular atrophy: a systematic literature review
Spinal muscular atrophy (SMA) is a rare, hereditary, autosomal recessive neuromuscular disorder that, in its most severe forms, impacts infants and children. Once symptomatic, it is characterized clinically by a distinct inability to achieve motor milestones, such as the ability to lift the head, sit, stand, or walk. Quality of life (QOL) measurement in very young infants presents a particular challenge. Therefore, this review aims to highlight commonly used measurement tools and identifies future research opportunities for QOL measurement in SMA.
A systematic literature review was carried out focusing on the various tools used to measure QOL in children < 18 years of age with formally diagnosed SMA type I, II, or III. Although the disease area of interest was SMA, data on Duchenne’s muscular dystrophy were also included because of the rare nature of SMA.
The Pediatric Quality of Life Inventory was the most commonly utilized tool to measure QOL in children; this included the generic and neuromuscular modules. No disease-specific tool to capture QOL in children with SMA was identified. Additionally, no measurement tools exist for very young infants (i.e., under 12 months) with SMA Type 1.
Evolving standards of care will lead to increased interest by stakeholders, on the methods used to measure QOL in infants and children across all types of SMA. Generic tools may not adequately capture QOL changes in SMA, especially given the age group affected by the disease. Further research is required to explore the scope for a disease-focused approach.
KeywordsSpinal muscular atrophy Quality of life Literature review PedsQL
Financial support was made possible through a student internship with Biogen international for the corresponding author during the Ph.D. period. This paper was funded through an internship for Shalvaree Vaidya at Biogen International. However, the internship was not contingent on the completion nor results of this review.
- 4.European Medicines Agency. (2017). Spinraza. Retrieved August 07, 2017, from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004312/human_med_002119.jsp&mid=WC0b01ac058001d124.
- 13.Eiser, C., & Morse, R. (2001). Quality-of-life measures in chronic diseases of childhood. Health Technology Assessment (Winchester, England), 5(4), 1–157.Google Scholar
- 17.Davis, S. E., et al. (2010). The PedsQL™ in pediatric patients with Duchenne muscular dystrophy: Feasibility, reliability, and validity of the pediatric quality of life inventory neuromuscular module and generic core scales. Journal of Clinical Neuromuscular Disease, 11(3), 97–109.CrossRefGoogle Scholar
- 21.Davis, E., et al. (2016). Measuring the quality of life of children and adolescents☆, in reference module in biomedical sciences. New York: Elsevier.Google Scholar
- 38.Varni, J. (2017). Pediatric Quality Of Life Inventory™ Neuromuscular Module (PedsQL™ Neuromuscular Module). Retrieved from https://eprovide.mapi-trust.org/instruments/pediatric-quality-of-life-inventory-neuromuscular-module.
- 49.Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). How young can children reliably and validly self-report their health-related quality of life?: An analysis of 8,591 children across age subgroups with the PedsQL™ 4.0 Generic Core Scales. Health and Quality of Life Outcomes, 5(1), 1.CrossRefGoogle Scholar
- 50.Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). Parent proxy-report of their children’s health-related quality of life: An analysis of 13,878 parents’ reliability and validity across age subgroups using the PedsQL™ 4.0 Generic Core Scales. Health and Quality of Life Outcomes, 5(1), 1.CrossRefGoogle Scholar